[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
2019 Bio Top5 인터뷰
스폰서배너광고 안내  배너1
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
이종욱 (Jong Wook Lee) 저자 이메일 보기
가톨릭대학교 의과대학, 서울성모병원
조회 422  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
열기 Authors and Affiliations


Aplastic anaemia is a rare, life-threatening condition, characterised by pancytopenia with hypocellular bone marrow. Haematopoietic stem cells and most progenitor cells express thrombopoietin receptor (c-MPL). Romiplostim is a peptibody with c-MPL agonist activity that stimulates endogenous thrombopoietin production and leads to promoting the proliferation and differentiation of megakaryocytes in the bone marrow. In this phase 2 trial we aimed to assess the activity and safety of romiplostim in patients with aplastic anaemia who were previously treated with immunosuppressive therapy.

We did an open-label, phase 2 study including a randomised, parallel, dose-finding part followed by an extension part to evaluate long-term treatment at two clinical centres in Seoul, South Korea. Eligible patients were aged 19 years or older, and had aplastic anaemia confirmed by bone marrow and cytogenetic studies and thrombocytopenia (platelet count ≤30 × 109/L), an Eastern Cooperative Oncology Group performance status score of 2 or lower, and were previously treated with immunosuppressive therapy, including at least one course of antithymocyte globulin plus cyclosporin. In the dose-finding part, patients were randomly assigned to fixed dose cohorts (1, 3, 6, or 10 μg/kg) of subcutaneous romiplostim once weekly for 8 weeks, according to a static allocation procedure after stratification by platelet count. In the extension part of the study, patients continued romiplostim titrated every 4 weeks in single steps (1, 3, 6, 10, 13, 16, and 20 μg/kg once weekly), depending on platelet response and safety up to 1 year (weeks 9–52). Patients who had a platelet response during weeks 46–53 continued dose titration in single steps (3, 6, 10, 13, 16, and 20 μg/kg once weekly) for an additional 2 years (weeks 53–156). The primary endpoint was the proportion of patients achieving a platelet response at week 9 (after completion of the dose-finding part). Activity was assessed per-protocol in all patients evaluable for response at week 9 and safety was assessed in all patients who received at least one dose of romiplostim. This trial is registered with ClinicalTrials.gov, NCT02094417.

Between April 14 and Nov 24, 2014, 35 patients were enrolled and randomly assigned to one of four dose cohorts: romiplostim 1 μg/kg (n=7), 3 μg/kg (n=9), 6 μg/kg (n=9), and 10 μg/kg (n=10). Data cutoff for this final analysis was on April 14, 2018. The median duration of treatment for all patients was 53 weeks (IQR 35–155). Ten (30%) of 33 evaluable patients achieved a platelet response at week 9, including seven (70%) of ten patients in the 10 μg/kg cohort, three (33%) of nine patients in the 6 μg/kg cohort, and no patients in both the 3 μg/kg and 1 μg/kg cohorts. During the extension study, 18 (55%) of 33 evaluable patients had a platelet response during weeks 46–53 and were eligible for continued treatment. Ten (30%) patients maintained a platelet response at 2 and 3 years, of whom nine had an erythroid response and five a neutrophil response, and completed protocol treatment. Treatment-related adverse events occurred in three (9%) of 35 patients, including grade 1 or 2 myalgia, fatigue, and dizziness. 17 (49%) of 35 patients had adverse events of grade 3 or higher; seven (20%) had serious adverse events (one event of febrile neutropenia, cataract, retinal detachment, macular fibrosis, inguinal hernia, appendicitis, cellulitis, tendon injury, and transfusion reaction); and one patient died from sepsis during treatment; none of these events were related to treatment. No patients developed clonal evolution.

Romiplostim seems to be active and has a favourable safety profile in patients with refractory aplastic anaemia. 10 μg/kg once weekly might be used as a recommended starting dose in future studies. These findings warrant further investigation.

Kyowa Hakko Kirin Korea.

- 형식: Research article
- 게재일: 2019년 08월 (BRIC 등록일 2019-09-02)
- 연구진: 국내(교신)+국외 연구진태극기
- 분야: Medicine
Leucyl-tRNA synthetase 1에 의한 포도당 의존적 류신 감지 및 대사 조절[Science]
발표: 윤이나 (서울대학교)
일자: 2020년 2월 28일 (금) 오후 02시 (한국시간)
언어: 한국어
참석자 접수신청하기
NK세포에 의한 손상된 말초신경 제거 기전 – 새로운 만성통증 치료법[ Cell ]
발표: 오석배 (서울대학교)
일자: 2020년 3월 5일 (목) 오전 10시 (한국시간)
언어: 한국어
참석자 접수신청하기
ATAD5가 복제 스트레스 상황에서 복제를 재개하는 세포생물학적 기작[ Nat. Commun.]
발표: 박수형 (기초과학연구원)
일자: 2020년 3월 12일 (목) 오후 03시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
이종욱 님 전체논문보기 >
장준호 (성균관대학교 의과대학, 삼성...)
관련분야 논문보기

Google (by Jong Wook Lee)
Pubmed (by Jong Wook Lee)
프리미엄 Bio일정 Bio일정 프리미엄 안내
[BRIC Webinar]NK세포에 의한 손상된 말초신경 제거 기전 – 새로운 만성통증 치료법[Cell]
[BRIC Webinar]Leucyl-tRNA synthetase 1에 의한 포도당 의존적 류신 감지 및 대사 조절[Science]
[고용부 재직자 무료과정]의료기기 GMP의 이해 과정
[고용부 재직자 무료과정]의료기기 GMP의 이해 과정
날짜: 2020.03.09~11
장소: 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실
2020 서경배과학재단 신진과학자 연구지원 프로그램
2020 서경배과학재단 신진과학자 연구지원 프로그램
날짜: 2020.03.31
주관: 서경배과학재단
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS